RESONATE-2: 7-year follow-up data

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.
Prof. Paolo Ghia discusses the latest 7-year follow-up IMBRUVICA® data in 1L CLL RESONATE-2 reinforces confidence in long-term survival with IMBRUVICA®, including those with high-risk genetic features[1]